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Abstract. FDA’s critical path initiative documents have focused on the challenges involved in the
development of new drugs. Some of the focus areas identified apply equally to the production of generic
drugs. However, there are scientific challenges unique to the development of generic drugs as well. In
May 2007, FDA released a document “Critical Path Opportunities for Generic Drugs” that identified
some of the specific challenges in the development of generic drugs. The key steps in generic product
development are usually characterization of the reference product, design of a pharmaceutically
equivalent and bioequivalent product, design of a consistent manufacturing process and conduct of the
pivotal bioequivalence study. There are several areas of opportunity where scientific progress could
accelerate the development and approval of generic products and expand the range of products for which
generic versions are available, while maintaining high standards for quality, safety, and efficacy. These
areas include the use of quality by design to develop bioequivalent products, more efficient
bioequivalence methods for systemically acting drugs (expansion of BCS waivers, highly variable drugs),
and development of new bioequivalence methods for locally acting drugs.
KEYWORDS: bioequivalence; critical path initiative; generic drugs.
INTRODUCTION
In 2004, FDA introduced the Critical Path Initiative (1)
that focused attention on the challenges involved in the
development of new drugs. After two years, a follow up set of
specific opportunities was created based on response to the
original initiative (2,3). While some areas apply equally to the
production of generic drugs, there are scientific challenges
unique to the development of generic drugs. In May 2007,
FDA released a document “Critical Path Opportunities for
Generic Drugs” that identified some of the specific challenges
in the development of generic drugs (4). The goal of this
document was to bring these challenges to the attention of
interested parties and identify opportunities for collaborative
solutions.
The need to address generic drug development was
motivated by the large and growing use of generic drugs.
Generic drugs represented 66.4 percent of the total prescrip-
tion doses sold in 2004, compared with 61 percent in 2001 (5).
Efforts to encourage efficient pharmaceutical manufacturing
processes and quality by design will only have maximum
impact when they are applied to generic drugs. While the
focus of the critical path initiative for generic drugs is on
generic drug development for the US, the scientific challenges
and their resolutions may have impact on ensuring generic
product quality in other markets.
The impact of generic competition is felt immediately
upon the approval of the first generic products. The Office of
Generic Drugs (OGD) website contains an analysis of IMS
sales data (wholesale prices) for single-ingredient brand name
and generic drug products sold in the U.S. from 1999 through
2004 (6). This analysis indicates that the appearance of a
second generic manufacturer reduces the average generic
price to nearly half the brand name price. As additional
generic manufacturers market the product, the prices contin-
ue to fall. For products that attract a large number of generic
manufacturers, the average generic price falls to 20% of the
branded price.
These results show the value to the consumer of having
multiple generic drug products competing in the market.
However, there are still products and product categories for
which there is limited or no generic competition, even though
all patent and exclusivity protection for the reference product
has expired. In order to understand this we need to take a
more detailed look at the generic drug development process
and identify the scientific reasons for the lack of competition.
This investigation lead to the critical path opportunities
identified in the May 2007 FDA report.
GENERIC DRUG DEVELOPMENT PROCESS
The steps involved in the development of a potential
generic product can be described in Fig. 1:
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not necessarily reflect the views or policies of the FDA.Unlike the case for new drugs, the risk of total failure is
low because the safety and efficacy of the active ingredient
have already been established, but cost efficiency is more
important because of much lower profit margins and compe-
tition with other generic manufacturers. Time efficiency is
important to both generic and new drug manufacturers with
neither wanting unanswered scientific questions to slow the
progress of products through the development process.
Another aspect to efficient drug development is to use
scientific understanding to limit unnecessary human testing
of drugs. Bottlenecks to the efficient development (in the
senses of resources, time, and appropriate use of human
subjects) of a generic products can occur at every stage in the
development process.
In the characterization stage, some generic products are
challenges to develop because of the complexity of the
reference product. Complex reference products may include
drug substances with many potentially active molecules.
Molecular diversity can arise in products with a natural
source origin or even in synthetic molecules that are
polydisperse mixtures. Other challenging reference products
include products with complex supra-molecular structures
such as iron complexes and products containing liposomes.
The use of nanotechnology in drug delivery will lead to even
more complex pharmaceutical structures to characterize. To
make a copy of these products, an ANDA sponsor may need
better characterization than the originator.
In the formulation development stage, generic formula-
tions may be developed that do not pass the bioequivalence
study or meet other requirements and formulation develop-
ment must be repeated. These failures can sometimes be
linked to the inability of dissolution or lack of an IVIVC to
evaluate proposed formulations and processes during devel-
opment. For new or complex dosage forms the formulation
and product development stage can fail because of an
inability to identify the critical quality attributes of new or
complex dosage forms. Inhalers are complex combination of
device and formulation and many are breath actuated and
thus must perform equivalently to the reference product over
a range of flow rates. Transdermal products must be
bioequivalent to the RLD in terms of the rate and extent of
drug delivery, but must also be equivalent in terms of
adhesion, irritation and sensitization to the RLD when
applied to the skin. Concern about the interaction of modified
release formulations with alcohol (7), has introduced a new
potentially critical quality attribute for some drug products.
The type of bioequivalence study required can determine
whether the development process is economically and scien-
tifically feasible. Expensive, extensive or unpredictable BE
tests can limit the development of a generic product. A highly
variable drug may require a large number of subjects using
the usual FDA recommended study. However, the biggest
limitation to generic competition is when FDA recommends a
clinical endpoint bioequivalence study. Many generic compa-
nies do not develop products that need clinical endpoint
bioequivalence studies because of the relative cost, time and
risk of failure involved. Clinical endpoint studies can add up
to $2–6 million to the cost
1. Thus, when expensive and risky
(to the sponsor) clinical endpoint trials are needed to
establish bioequivalence, the number of generic competitors
is reduced significantly.
Finally, a generic drug that demonstrates bioequivalence
to the reference product can be delayed in reaching the
market because of the final scale-up step in the generic drug
development process. Problems on scale up include wasted
commercial batches, failure to meet specifications, and
process variability. These problems may require the sponsor
to reformulate product or revise the process.
CRITICAL PATH OPPORTUNITIES
Based on this analysis of generic drug development,
there are several areas of opportunity where scientific
progress could accelerate the development and approval of
generic products and expand the range of products for which
generic versions are available, while maintaining high stand-
ards for quality, safety, and efficacy. FDA presented these
opportunity areas in its May 2007 document (4).
& Improve the science underlying quality by design for
the development and manufacture of generic drug
products.
& Improve the efficiency of current methods for assess-
ment of bioequivalence of systemically acting drugs
including products that use complex and novel drug
delivery technologies.
& Develop methods for the assessment of bioequiva-
lence of locally acting drugs such as topical and
inhalation products.
& Develop methods for characterizing complex drug
substances and products.
Figure 2 indicates how these opportunity areas link into
the generic drug development process. Progress in these areas
will accelerate approval of generic drug products. More
importantly, it will expand the range of products for which
generic versions are available, while maintaining high stand-
ards for quality, safety, and efficacy. Methods for equivalence
based on sound science build the confidence of health care
providers, patients, and the public that generic products are












Fig. 1. Development of a generic drug product
1 We use an estimate of $10,000 per subject as an estimate based on
costs of phase III trials reported in the literature [8,9,10]. We
assume a study size of 200–600 subjects.
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In this paper we focus on the critical path opportunities
that are connected to the evaluation of bioequivalence.
& Quality by design tools to aid in the design and man-
ufacture of bioequivalent products
& Bioequivalence of systemic drugs
& Bioequivalence of locally acting drugs
Quality by Design for Bioequivalence
Quality by design (QbD) is often discussed in the context
of CMC submission or manufacturing process understanding.
Especially for generic drugs, which have very specific
performance goals (bioequivalent to the RLD); QbD tools
to aid in the design and manufacture of bioequivalent
products are desirable.
QbD identifies characteristics that are critical to quality
from a safety and efficacy perspective, translates them into
the attributes that the drug product should possess, and
establishes how the critical process parameters can be varied
to consistently produce a drug product with the desired
attributes. This is achieved by establishing a relationship
between formulation and manufacturing process variables
(including drug substance and excipient attributes and
process parameters) and product quality, and identifying the
sources of product variability.
TouseQbDtodevelopaproductthatisbioequivalenttoa
reference product, a generic sponsor must have an under-
standing of what attributes of the formulation and manufac-
turing process have the potential to change the bioavailability
of a particular active ingredient.
Current formulation development strategies for generic
drugs are mainly empirical. Within a QbD process, modeling
and simulation using improved absorption models could help
a generic sponsor identify the formulation and manufacturing
variables to be adjusted to make the product bioequivalent.
Based on the properties of the active ingredient (solubility,
permeability, interactions with metabolic enzymes and trans-
porter proteins), integrated absorption models could be used
to estimate (or in some cases predict) the relation between an
in vivo dissolution or release rate and the pharmacokinetics
parameters that are used to evaluate bioequivalence. The
current state of modeling and simulation tools does not allow
this type of formulation development from a mechanistic
understanding. However, progress could be made through
looking at data from a wide variety of drugs/formulations.
Modeling and simulation can aid generic developers in
determining what drug release profile is needed to provide
bioequivalence to the reference product. Then the challenge
to the generic developer becomes the selection of excipients
and design of a formulation and release mechanism that will
provide the intended in vivo release profile. Mechanistic
understanding of how physical properties of drug substance
and excipients affect drug product performance can enable
rational choices of excipients and reduce the number of
experimental formulations that need to be produced.
Because it is usually not feasible to test every trial
f o r m u l a t i o ni na nin vivo study, better in vitro/in vivo
correlations (IVIVC) will give better feedback within an
iterative design process. When an in vitro dissolution test can
be related to the in vivo dissolution of a product, a generic
sponsor would have an efficient tool to evaluate different
formulations and select the optimal formulation for use in the
pivotal bioequivalence study. However, the correlation of
dissolution testing with in vivo performance varies from
product to product. FDA’s data from dissolution tests and
pharmacokinetic studies could help external collaborators
develop and test models capable of predicting the connection
between dissolution and bioavailability/bioequivalence.
FDA’s guidance on the establishment of IVIVCs (11) has
not been used extensively by ANDA sponsors because it
requires the performance of multiple in vivo pharmacokinetic
studies with different formulations to establish an IVIVC.
This guidance then allows the IVIVC to be used for
regulatory purposes in place of in vivo pharmacokinetic
studies. This process has not been of value to ANDA
sponsors. However, an understanding (even a theoretical
one) of the relation between in vitro tests and in vivo
performance is very valuable to ANDA sponsors during the
product development process. It is part of the critical path
opportunity to identify and resolve the scientific issues that
limit the use of IVIVCs by ANDA sponsors.
Bioequivalence for Systemically Acting Drugs
For systemically acting drugs, the critical path goal is to
increase the efficiency of a process that already is providing
safe and effective generic drugs to the public. The use of the
Biopharmaceutics Classification System (BCS) (12,13) in the
development of both new and generic drug products is an
example of how critical path approaches can improve the
efficiency of pharmaceutical development and improve prod-
uct quality. Expanding the use of biowaivers in appropriate
cases and improving dissolution methods are efficient ways to
accelerate the approval and development of high quality
generic products. FDA has also identified other issues for
which resolution could lead to more efficient bioequivalence
testing. Many of these areas were discussed in scientific detail
at the May 2007 AAPS BE, BCS and Beyond workshop and
examples included
& Expansion of BCS biowaivers to some class II and
class III drugs (14)
& Development of biorelevant dissolution (15,16,17)
& Mechanistic understanding of food effects











Fig. 2. Critical Path areas linked to development of generic drug
products
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Bioequivalence of locally acting drugs is a long standing
challenge to the generics program, has the biggest impact on
generic competition, and raises the most challenging scientific
issues. Locally acting drugs are primarily found in the
following categories: topical dermatological products, orally
inhaled and nasal drug products, and GI acting drug products.
They often require exploration of alternative bioequivalence
methods because plasma concentration profiles of these
products are not always appropriate surrogates of pharmaco-
logical activity. There was little discussion of these issues at
the May 2007 AAPS BE, BCS and Beyond workshop. It is
the intention of the “Critical Path Opportunities for Generic
Drugs” report to attract the attention of leading scientists to
address these complex challenges.
Difficulty in demonstrating bioequivalence of local acting
drugs also has consequences to NDA sponsors across a
product’s life cycle. In initial development, process scale-up
and optimization become difficult if there is not a method to
compare pre and post change products. After approval,
manufactures are reluctant to make major manufacturing
improvements if a clinical study is required to validate the
changes.
The selection of the bioequivalence method for a locally
drug is based on product specific factors and a scientific
understanding of the products’ mechanism of action. FDA’s
regulation 21 CFR 320.24 lists approaches that are acceptable
for determining the bioavailability or bioequivalence of a drug
product. All of the approaches listed have been used for
bioequivalence of locally acting drugs. A 2003 addition to the
Federal Food Drug and Cosmetic Act at Section 505(j)(8)(A)
(ii)indicates that “For a drugthat isnot intended to beabsorbed
intothebloodstream,theSecretarymayassessbioavailabilityby
scientifically valid measurements intended to reflect the rate
and extent to which the active ingredient or therapeutic
ingredient becomes available at the site of drug action”.
Clinical Endpoint Bioequivalence Study
Even though 21 CFR 320.24 indicates that “This
approach is the least accurate, sensitive, and reproducible of
the general approaches for measuring bioavailability or
demonstrating bioequivalence.” for many locally acting drugs,
FDA recommends a bioequivalence study with clinical
endpoints. It has become the fall-back method because
selection of one of the other approaches depends on scientific
understanding for a particular drug product, but all drugs
have a clinical endpoint used to support their initial approval.
A bioequivalence study with clinical endpoints will use a
product-specific clinical indication recommended by FDA.
Patients in the study would be given the test product, the
reference product, and/or a placebo. The placebo arm ensures
that the study and its conduct are sufficiently sensitive to
differences between treatments. If the reference product is
labeled for multiple indications, then the indication that is
most sensitive to difference in local delivery of drug is usually
preferred. The ability of clinical endpoint bioequivalence
studies to detect differences in formulation performance
between products depends on the exposure–response relation
for the particular drug and indication.
Most clinical endpoint bioequivalence studies have a
dichotomous endpoint; the treatment either succeeds or fails.
To decide if the test product is bioequivalent to the reference,
the success proportion for each treatment is calculated, and if
the 90% confidence interval for the difference in success is
within −20% to + 20%, then the test product passes. For
dichotomous endpoints, there is no meaning to between-
subject variability and generally studies must enroll approx-
imately 200 to 600 subjects to ensure sufficient power.
Table I provides some example results of clinical studies
used in support of ANDAs. All of these studies had three arms
and used the difference in cure rate as the endpoint with an
acceptable 90% confidence interval of −20 to + 20 percentage
points. The results show that even with relatively large
numbers of patients in each study, the confidence intervals
were close to the limits defined by FDA. This suggests that
these studies were at a high risk of failure to demonstrate
bioequivalence.
Because clinical endpoint bioequivalence studies can
be larger than studies conducted in support of the initial
NDA
2 and the insensitivity of some clinical endpoints to
formulation differences, there is much interest in alternate
bioequivalence methods that are more efficient and more
sensitive at detecting product differences.
In Vitro Study
In vitro bioequivalence studies have been used for some
locally acting products. Examples include an in vitro binding
assay for cholestyramine (20) and dissolution studies for some
immediate release GI acting products that are high solubility.
Open scientific questions remain for immediate release GI
acting products that are low solubility and modified release
GI acting products.
For nasal and inhalation products, in vitro equivalence
tests are a critical aspect of evaluate the performance of the
device. For solution products, in vitro tests alone demonstrate
bioequivalence, while for suspension products the in vitro
tests are combined with PK, PD, or clinical endpoint studies
as needed to ensure equivalence local delivery (21).
TheSUPAC-SS(22) guidance discusses the role of in vitro
release testing for semi-solid dosage forms. The guidance states
that “An in vitro release rate can reflect the combined effect of
several physical and chemical parameters, including solubility
and particle size of the active ingredient and rheological
properties of the dosage form. In most cases, in vitro release
rate is a useful test to assess product sameness between pre-
change and post-change products.” The use of in vitro release
tests is currently limited to evaluating changes in manufactur-
ing process or scale-up by the same manufacturer and is not
used for bioequivalence. However, when the test and the
2 Approval of a new drug product requires that “adequate and well-
controlled studies” demonstrate that the product is safe and
effective. These clinical studies may either demonstrate superiority
over placebo or non-inferiority over an active control that is
approved for the same indication that is being sought for the new
product. Demonstrating equivalence requires both that the study be
sensitive enough to detect differences between products and that it
show equivalent clinical efficacy between the products and thus can
require a larger study.
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ences are in manufacturing and process scale.
Pharmacokinetic Study
For locally acting products plasma concentrations may be
appropriate for use in a bioequivalence study when the
plasma concentration reflects the delivery to the site of
action. In the GI-acting category, pharmacokinetic bioequi-
valence studies have been used for mesalamine pro-drugs
(23). For topical drugs applied to the skin the amount of drug
that reached the systemic circulation from a topical dermato-
logical products was typically not detectable. With advances
in assays, many drugs can be detected and compared. For
some topical products, such as lidocaine/prilocaine cream
(24), pharmacokinetic studies have been accepted by FDA as
evidence for bioequivalence. However, using a pharmaco-
kinetic study requires that the area of drug application be
similar between test and reference products.
Pharmacodynamic Study
Another approach to bioequivalence of locally acting
drugs is to measure a pharmacodynamic effect of the drug.
The pharmacodynamic endpoint can differ from the clinical
effect of the product. It is generally needed to demonstrate
the dose-response of the pharmacodynamic endpoint.
For topical corticosteroids, there is a 1995 FDA guidance
(25) that describes a pharmacodynamic bioequivalence study
(26,27,28,29). As in all pharmacodynamic bioequivalence
studies, it is necessary to establish sufficient sensitivity in the
dose–response curve to detect differences between products.
For the skin blanching study, the dose is varied by changing the
amount of time the topical product is applied to the skin. A
pilot study using a range of application times of the reference
product is used to identify patients in whom skin blanching is
sensitive to differences in application time. Then, these patients
are used to compare the test and reference products.
For inhalation products, pharmacodynamic measures of
lung function have been used in the approval of ANDAs for
albuterol MDIs (30). These applications used histamine PC20
or FEV1 as the endpoints. Equivalence of local delivery using
these endpoints was evaluated using a “dose-scale” method,
in which the relative bioavailability is determined in terms of
dose of the test formulation required to produce an equiva-
lent PD response to the reference product (31).
New Methods for Locally Acting Drugs
In general, the alternatives to clinical endpoint studies
are preferable because of sensitivity and efficiency, but the
alternatives need to be scientifically justified. The 2007 critical
path report (4) identifies possible research directions to
address these problems that include:
& Molecular Level Imaging: Imaging techniques that
can quantify the amount of drug at the site of action
can be used to validate new in vitro tests or new
biomarkers. In the past OGD, has rejected for direct
use in bioequivalence testing any imaging technique
that would require modification or labeling of the
reference product. However, new methods that do
not require product modification could be used
directly as a bioequivalence method.
& In Vivo Sampling Methods: Direct sampling of target
tissue (for example by microdialysis (32,33,34,35)o r
tape stripping (36,37,38,39,40,41,42,43,44,45) for der-
matologicalproducts)could be used as a bioequivalence
method when blood concentrations are not appropriate.
& Pharmacodynamic Measures: New pharmacodynamic
measures (biomarkers) that are sensitive to local drug
concentrations can be used for bioequivalence test-
ing. When we discuss biomarkers for bioequivalence
our goal is to identify biomarkers of local delivery.
Other studies on the reference product have already
established safety and efficacy. An example that is
under investigation by FDA is exhaled NO as a
marker of local delivery of an inhaled corticosteroid
(46,47,48,49). For use in a bioequivalence study a
biomarker must have an exposure–response relation
that allows sensitivity.
& Novel Pharmacodynamic Study Designs: Many asth-
ma drugs have a very shallow dose–response curve
and exhibit high within- and between-subject variabil-
ity,requiring the use of a very largenumber of subjects
in a pharmacodynamic equivalence test. Novel phar-
macodynamic study designs that enable using a forced
expiratory volume in 1 second (FEV1) endpoint in a
crossover study would allow bioequivalence studies
to be conducted using a much smaller number of
subjects (50).
& Design of Bioequivalence Trials with Clinical End-
points: New approaches to design clinical trials with
the goal of more efficiently demonstrating equiva-
lence could be investigated. Sometimes, pharmaco-
kinetic methods cannot be used to assess generics for
approval, and we have to use trials with clinical end-
points or pharmacodynamic measures. In such cases,
there is interest in better understanding when non-
inferiority trial designs can be used (51,52,53).
& Particle Size Measurement for Suspension Bioequiva-
lence: For many locally acting products that contain
suspended drug, in vivo bioequivalence studies are
requested because the particle size distribution in the
suspensions cannot be directly compared (21). Some
of the challenges in developing these methods are to
distinguish drug particles from other particles in the
product and to ensure that the measurement process
does not itself affect the particle size. For non-
spherical particles there are other challenges (54).
Once this measurement is possible with sufficient
accuracy and precision, a demonstration of equivalent
particle size in combination with other relevant
characterizations of particle properties could be used
Table I. Example Clinical Endpoint Study Sizes for a Topical Anti-
fungal Drug (19)
N %Cure Test %Cure Ref 90%CI
728 50 48 [−12, + 16]
453 46 40 [−8, + 20]
447 29 27 [−9, + 13]
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as is done for solution products.
CONCLUSIONS
The FDA role in the critical path initiative is to identify
the challenges as it did in 2004 for new drugs and in 2007 for
generic drugs. This initial report on critical path opportunities
for generic drugs is intended to stimulate discussion and
comments. In response to this input from interested parties
including industry, academia, other government agencies
(NIH, NSF, NIST), and the public, FDA intends to participate
in collaborative solutions to these critical path challenges.
A challenge in bringing together consortia that involve
industrial sponsors is that the generic sponsors are in direct
competition with each other for the same product (this differs
from new drugs where companies may compete with different
products for the same clinical indication or therapeutic area).
Thus an ANDA sponsor that invests efforts to address one of
these issues will be aiding their competitors who may gain the
advantage of scientific advances without any investment. This
may require the design of new types of consortia with
tangible benefits for participation.
A potential solution is for consortia to establish domains
of “pre-competitive knowledge” that can be shared freely and
openly (55). For example, a consortium may be assembled to
develop and present evidence that convinces FDA to
establish a new bioequivalence method for a particular class
of products. Each ANDA sponsor would then develop their
own product and use this method to establish bioequivalence
to the reference product.
Solutions to many of these critical path challenges could
result in large savings to the public. For example, for a drug
with $500 million dollars/year in sales that has no generic
competition due to scientific challenges, development of a
new bioequivalence method could save the public hundreds
of million dollars per year. Even an investment as large as
$10 million to establish a new bioequivalence method for this
product category, would give a large return on investment to
the public. However, any individual generic manufacturer
that invested $10 million in a bioequivalence method for a
product might never be able to recover that investment
because of competition with other generic manufactures.
Thus, identifying the source for resources to apply to these
critical path opportunities is a challenge.
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